Table 4.

Outcomes and complications.

Parameter; Median (IQR) or n (%)	Interferon group (n = 33)	Control group (n = 33)	p-value
Time to clinical response, median(IQR) (days)	9(6–10)	11(9–15)	0.002
ICU admission, n (%)	14(42.42)	22(66.66)	0.04
Intubation requirement	2(6.06)	6(18.18)	0.12
Length of stay in ICU (days), median (IQR) (days)	9(6–13)	8 (4–12)	0.55
Length of stay in hospital (days), median (IQR) (days)	11(9–13)	13(10–17)	0.05
All-cause mortality at day 28	2(6.06)	6(18.18)	0.12
Six category scale at day 7 of intervention			OR(95% CI)
1- Death	0	1(3.03)
2- Hospital admission, requiring invasive mechanical ventilation	2(6.06)	4(12.12)
3- Hospital admission, requiring high-flow nasal cannula or non-invasive mechanical ventilation	0	3(9.09)
4- Hospital admission, requiring supplemental oxygen	26(78.79)	23(69.69)
5- Hospital admission not requiring supplemental oxygen	0	0
6- Discharge	5(15.15)	2(6.06)	2.76(0.49–15.42)
Six category scale at day 14 of intervention
1- Death	1(3.03)	3(9.09)
2- Hospital admission, requiring invasive mechanical ventilation	1(3.03)	3(9.09)
3- Hospital admission, requiring high-flow nasal cannula or non-invasive mechanical ventilation	1(3.03)	0
4- Hospital admission, requiring supplemental oxygen	4(12.12)	9(27.27)
5- Hospital admission not requiring supplemental oxygen	0	0
6- Discharge	26(78.79)	18(54.55)	3.09(1.05–9.11)
Six category scale at day 28 of intervention
1- Death	2(6.06)	6(18.18)
2- Hospital admission, requiring invasive mechanical ventilation	0	0
3- Hospital admission, requiring high-flow nasal cannula or non-invasive mechanical ventilation	0	0
4- Hospital admission, requiring supplemental oxygen	0	0
5- Hospital admission not requiring supplemental oxygen	0	0
6- Discharge	31(93.94)	27(81.82)	3.44(0.64–18.50)